Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an average annual return of 12.68%. Currently, Vertex Pharmaceuticals has a market capitalization of $106.01 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports. A number of other equities research analysts have also commented on VRTX.

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing,

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

The FDA is scheduled to make an approval decision for suzetrigine in treating acute pain by Jan. 30, 2025. This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 and over the next few years.